Morphine and naloxone: effects on conditioned fear as measured with the potentiated startle paradigm.

Morphine (0.6 to 10 mg/kg) produced a dose-dependent reduction of the potentiated startle effect where acoustic startle amplitude is normally increased in the presence of a light previously paired with a shock. The effect was selective since the same doses did not appreciably depress baseline levels of startle. Naloxone (2 mg/kg) did not significantly affect potentiated startle, but antagonized the ability of morphine (10 mg/kg) to block potentiated startle. Morphine did not block potentiated startle by accelerating extinction. The advantages of this paradigm for studying fear or anxiety were discussed.     

Concurrent etonitazene and water intake in rats: Role of taste,olfaction, and auditory stimuli

Diazepam (0.3, 0.6, 1.2, or 2.5 mg/kg) produced a dose-dependent reduction of the potentiated startle effect where acoustic startle amplitude is normally increased in the presence of a light previously paired with a shock. Even the lowest dose tested (0.3 mg/kg) significantly attenuated potentiated startle. The effect was selective since the same doses did not depress baseline startle amplitude measured in the same animals in the same test session. A 2×2 design in which rats were trained and tested under the same or different drug condition (diazepam or saline) showed the results could not be explained by state-dependent learning. The primary effect of diazepam was to block expression of rather than acquisition of fear as measured by potentiated startle. Flurazepam (2.5, 10, or 20 mg/kg) also reduced potentiated startle selectively but was 6–8 times less potent than diazepam. These and other results suggest that the potentiated startle paradigm, as a measure of classical conditioning that involves no operant, might provide a useful adjunct to behavioral methods currently being used to analyze antianxiety compounds.     

Effects of threat of electric shock and diazepam on the N1/P2 auditory-evoked potential elicited by low-intensity auditory stimuli

The acoustic startle response includes rapid muscular contractions elicited by loud sounds; it may be measured in humans as the electromyographic response of the orbicularis oculi muscle. Enhancement of this response during exposure to threat of electric shock (fear- potentiated startle) is a widely used model of human anxiety. A problem with the use of the startle reflex in studies of human anxiety is the aversiveness of startle-eliciting sounds, which may, in some subjects, exceed the aversiveness of the electric shock itself. We have recently found that the long-latency N1/P2 auditory-evoked potential elicited by loud sounds is subject to fear potentiation. However, it is not known whether N1/P2 potentials elicited by low-intensity sounds, which do not elicit the startle response, are also subject to fear potentiation. This study examined the susceptibility of the N1/P2 potential elicited by low-intensity sounds to fear potentiation, and the effect of the anxiolytic diazepam on the N1/P2 potential in the absence and presence of threat of electric shock. Fifteen male volunteers (18-43 years) participated in three sessions in which they received placebo, diazepam 5 mg and diazepam 10 mg according to a double-blind protocol. Sixty minutes after treatment, auditory-evoked potentials were elicited by 40 ms 1 kHz tones 5, 10, 15, 20 and 25 dB[A] above a background of 70 dB[A]. Recording sessions consisted of eight alternating 2 min THREAT and SAFE blocks; unpredictable shocks (1.8 mA, 50 ms) were delivered to the subject's wrist in THREAT blocks (1-4 shocks per block). The amplitude of the N1/P2 potential increased monotonically as a function of stimulus intensity. The responses were significantly greater during THREAT blocks than during SAFE blocks (fear potentiation). Diazepam attenuated the responses in both the SAFE and THREAT conditions. Fear potentiation of the N1/P2 potential was significantly reduced by diazepam. Diazepam reduced subjective alertness and lowered critical flicker fusion frequency, a measure of arousal. The results suggest that fear potentiation of the N1/P2 potential is not simply a manifestation of the fear-potentiated startle response. The use of low-intensity stimuli may be advantageous in studies of fear potentiation in humans.     

Acute Tryptophan Depletion Increases Translational Indices of Anxiety but not Fear: Serotonergic Modulation of the Bed Nucleus of the Stria Terminalis?

Serotonin is strongly implicated in the mammalian stress response, but surprisingly little is known about its mode of action. Recent data suggest that serotonin can inhibit aversive responding in humans, but this remains underspecified. In particular, data in rodents suggest that global serotonin depletion may specifically increase long-duration bed nucleus of the stria terminalis (BNST)-mediated aversive responses (ie, anxiety), but not short-duration BNST-independent responses (ie, fear). Here, we extend these findings to humans. In a balanced, placebo-controlled crossover design, healthy volunteers (n=20) received a controlled diet with and without the serotonin precursor tryptophan (acute tryptophan depletion; ATD). Aversive states were indexed by translational acoustic startle measures. Fear and anxiety were operationally defined as the increase in startle reactivity during short- and long-duration threat periods evoked by predictable shock (fear-potentiated startle) and by the context in which the shocks were administered (anxiety-potentiated startle), respectively. ATD significantly increased long-duration anxiety-potentiated startle but had no effect on short-duration fear-potentiated startle. These results suggest that serotonin depletion in humans selectively increases anxiety but not fear. Current translational frameworks support the proposition that ATD thus disinhibits dorsal raphé-originating serotonergic control of corticotropin-releasing hormone-mediated excitation of the BNST. This generates a candidate neuropharmacological mechanism by which depleted serotonin may increase response to sustained threats, alongside clear implications for our understanding of the manifestation and treatment of mood and anxiety disorders.     

The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle

Fear to predictable threat and anxiety to unpredictable threat reflect distinct processes mediated by different brain structures, the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST), respectively. This study tested the hypothesis that the corticotropin-releasing factor (CRF₁) antagonist GSK561679 differentially reduces anxiety but increases fear in humans. A total of 31 healthy females received each of four treatments: placebo, 50 mg GSK561679 (low-GSK), 400 mg GSK561679 (high-GSK), and 1 mg alprazolam in a crossover design. Participants were exposed to three conditions during each of the four treatments. The three conditions included one in which predictable aversive shocks were signaled by a cue, a second during which shocks were administered unpredictably, and a third condition without shock. Fear and anxiety were assessed using the acoustic startle reflex. High-GSK had no effect on startle potentiation during unpredictable threat (anxiety) but increased startle potentiation during the predictable condition (fear). Low-GSK did not affect startle potentiation across conditions. Consistent with previous findings, alprazolam reduced startle potentiation during unpredictable threat but not during predictable threat. The increased fear by high-GSK replicates animal findings and suggests a lift of the inhibitory effect of the BNST on the amygdala by the CRF₁ antagonist.     

Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats

The effect of acute or chronic administration of imipramine on fear-enhanced startle (potentiated startle) in rats was investigated. Thirty male albino rats were initially given preliminary startle testing, assigned to one of three matched groups, and trained for potentiated startle by presenting ten light-shock pairings on each of 2 days. Subsequent startle testing following a single injection of 0, 5 or 10 mg/kg imipramine revealed that the degree of startle potentiation (increased responding in the presence of the light previously paired with shock) was similar across treatment conditions. A significant and comparable potentiation of startle was observed in animals treated chronically with saline or imipramine (10 mg/kg/day) for 21 days between training and testing. Potentiated startle was also observed in these animals on the next (22 nd) day after injection of an additional dose of the drug (10 mg/kg) 5 min prior to testing. Plasma levels of imipramine and its metabolite, desipramine, were relatively high after each of these treatments. Since previous studies have shown that potentiated startle is decreased by diazepam, the present findings suggest that the potnetiated startle paradigm is a valid model for studying simple fear or anxiety rather than panic disorder.     

The effect of amobarbital sodium on conditioned fear as measured by the potentiated startle response in rats

Summary The startle response in rats to a sudden sound was increased when the startle was elicited in the presence of a flashing light (CS) which had previously been paired with electric shock. The magnitude of this potentiated startle was used as a measure of the conditioned fear elicited by the CS.The effects of different doses of amobarbital sodium on the potentiated startle, the startle in the presence of a flashing light which had not been paired with shock, and the startle to electric shock were tested. It was found that the drug reduced the magnitude of the potentiated startle response and reduced even more the startle to electric shock, but apparently had little, if any, effect on the startle to loud sound in the presence of a neutral CS. The effects lasted for at least 90 min after i.p. injections of the drug.The action of amobarbital was interpreted in terms of a selective reduction in the strength of the fear drive, but other interpretations were not ruled out.The fact that this drug produced differential effects on startle responses elicited in different ways, suggests that such responses may be useful measures of differential psychopharmacological effects.Work on this study was supported by Grant MY 2949 from the National Institute of Mental Health, United States Public Health Service.The author wishes to thank Dr. N. E. Miller who was consulted on every phase of the research and Dr. J. D. Davis who designed the transducer and suggested the system for recording startle responses.     

The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample

Rationale

To improve outcomes for patients undergoing extinction-based therapies (e.g., exposure therapy) for anxiety disorders such as post-traumatic stress disorder (PTSD), there has been interest in identifying pharmaceutical compounds that might facilitate fear extinction learning and recall. Oxytocin (OT) is a mammalian neuropeptide that modulates activation of fear extinction-based neural circuits and fear responses. Little is known, however, about the effects of OT treatment on conditioned fear responding and extinction in humans.

Objectives

The purpose of the present study was to assess the effects of OT in a fear-potentiated startle task of fear conditioning and extinction.

Methods

A double-blind, placebo-controlled study of 44 healthy human participants was conducted. Participants underwent a conditioned fear acquisition procedure, after which they were randomized to treatment group and delivered OT (24 IU) or placebo via intranasal (IN) spray. Forty-five minutes after treatment, participants underwent extinction training. Twenty-four hours later, subjects were tested for extinction recall.

Results

Relative to placebo, the OT group showed increased fear-potentiated startle responding during the earliest stage of extinction training relative to placebo; however, all treatment groups showed the same level of reduced responding by the end of extinction training. Twenty-four hours later, the OT group showed significantly higher recall of extinction relative to placebo.

Conclusions

The current study provides preliminary evidence that OT may facilitate fear extinction recall in humans. These results support further study of OT as a potential adjunctive treatment for extinction-based therapies in fear-related disorders.     

Oxytocin Reduces Background Anxiety in a Fear-Potentiated Startle Paradigm

Oxytocin reportedly decreases anxious feelings in humans and may therefore have therapeutic value for anxiety disorders, such as post-traumatic stress disorder (PTSD). As PTSD patients have exaggerated startle responses, a fear-potentiated startle paradigm in rats may have face validity as an animal model to examine the efficacy of oxytocin in treating these symptoms. Oxytocin (0, 0.01, 0.1, or 1.0 μg, subcutaneously) was given either 30 min before fear conditioning, immediately after fear conditioning, or 30 min before fear-potentiated startle testing to assess its effects on acquisition, consolidation, and expression of conditioned fear, respectively. Startle both in the presence and absence of the fear-conditioned light was significantly diminished by oxytocin when administered at acquisition, consolidation, or expression. There was no specific effect of oxytocin on light fear-potentiated startle. In an additional experiment, oxytocin had no effects on acoustic startle without previous fear conditioning. Further, in a context-conditioned test, previous light-shock fear conditioning did not increase acoustic startle during testing when the fear-conditioned light was not presented. The data suggest that oxytocin did not diminish cue-specific conditioned nor contextually conditioned fear, but reduced background anxiety. This suggests that oxytocin has unique effects of decreasing background anxiety without affecting learning and memory of a specific traumatic event. Oxytocin may have antianxiety properties that are particularly germane to the hypervigilance and exaggerated startle typically seen in PTSD patients.     

5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine

5-HT6 receptors have been implicated in consolidation of visuospatial and reward-based learning tasks. Since 5-HT6 receptors may be important in modulation of sensory gating which is often affected in schizophrenic patients, we tested whether Ro 4368554, a 5-HT6 selective antagonist at a dose of 10 mg/kg, could reverse the loss of prepulse inhibition from apomorphine or scopolamine. In addition, we also tested whether Ro 4368554 altered fear conditioning using fear potentiated startle, a model for emotional learning. Prepulse inhibition of startle was disrupted by apomorphine (0.5 mg/kg) when prepulse emissions were 5 dB above background but not above 15 dB, while scopolamine (0.5 mg/kg) caused disruption at both prepulse levels. Scopolamine-mediated disruption was not reversed by Ro 4368854 but apomorphine-mediated disruption was significantly ameliorated by 5-HT6 inhibition. For fear potentiated startle, scopolamine and/or Ro 4368554 were administered before two daily fear conditioning sessions; rats were tested on the following day. Rats that received scopolamine displayed no fear potentiated startle but Ro 4368554 reversed this scopolamine deficit. Additionally, we mapped Fos induction in rats treated with scopolamine and/or Ro 4368554; scopolamine increased Fos expression in the central nucleus of the amygdala and this was attenuated by Ro 4368554. In summary, we have demonstrated the efficacy of 5-HT6 antagonists in modulating sensory gating and fear conditioning, and thus may be of therapeutic use for schizophrenia-related disorders.     

Dopamine D2 receptor mechanisms in the expression of conditioned fear

The increase in the startle reflex in the presence of a stimulus that has been previously paired to foot shock is taken as an index of anxiety and named fear potentiated startle (FPS). Freezing behavior, defined as a cessation of all observable movements except those associated with respiration, has also been used as an index of fear in rats. Recently, a growing body of evidence has suggested that dopaminergic mechanisms are significant for different aspects of affective memory, namely its formation, expression or retrieval. However, the results of studies that have directly examined the ability of the dopaminergic system to influence fear have been inconsistent. This work is aimed at examining the involvement of D1 and D2 receptors in the acquisition and expression of conditioned fear using the fear potentiated startle test and the freezing behavior. We evaluated the effects of systemic administration of the D1 antagonist SCH 23390, the D1 agonist SKF 38393, the D2 antagonist sulpiride and the D2 agonist quinpirole before and after conditioning on FPS and freezing as indices of fear memory. The motor activity of the animals was also evaluated in an open field test. Injections of SCH 23390, SKF 38393, sulpiride and quinpirole before conditioning sessions did not produce any significant effect on FPS, but SCH 23390 decreased freezing. Injections of SCH 23390, SKF 38393 and sulpiride before testing session did not produce any significant effect on FPS or freezing. Quinpirole caused significant reduction in FPS and freezing when injected before testing. Drugs' actions were not due to nonspecific impairments in the ability to respond to the CS because the identical drug treatments had no effect in an open field test. Our findings indicate that DA mechanisms mediated by D2 receptors are mainly involved in the expression rather than in the acquisition of fear.     

Oxytocin Reduces Background Anxiety in a Fear-Potentiated Startle Paradigm: Peripheral vs Central Administration

Oxytocin is known to have anti-anxiety and anti-stress effects. Using a fear-potentiated startle paradigm in rats, we previously demonstrated that subcutaneously administered oxytocin suppressed acoustic startle following fear conditioning compared with startle before fear conditioning (termed background anxiety), but did not have an effect on cue-specific fear-potentiated startle. The findings suggest oxytocin reduces background anxiety, an anxious state not directly related to cue-specific fear, but sustained beyond the immediate threat. The goal of the present study was to compare the effects of centrally and peripherally administered oxytocin on background anxiety and cue-specific fear. Male rats were given oxytocin either subcutaneously (SC) or intracerebroventricularly (ICV) into the lateral ventricles before fear-potentiated startle testing. Oxytocin doses of 0.01 and 0.1 μg/kg SC reduced background anxiety. ICV administration of oxytocin at doses from 0.002 to 20 μg oxytocin had no effect on background anxiety or cue-specific fear-potentiated startle. The 20 μg ICV dose of oxytocin did reduce acoustic startle in non-fear conditioned rats. These studies indicate that oxytocin is potent and effective in reducing background anxiety when delivered peripherally, but not when delivered into the cerebroventricular system. Oxytocin given systemically may have anti-anxiety properties that are particularly germane to the hypervigilance and exaggerated startle typically seen in many anxiety and mental health disorder patients.     

Yohimbine — facilitated acoustic startle reflex in humans

Preclinical studies have suggested the acoustic startle reflex (ASR) may be a useful animal model to investigate the neurochemical basis of anxiety and fear states. This work has revealed that the anxiogenic alpha-2 receptor antagonist, yohimbine, increases the amplitude of the ASR in laboratory animals. The present investigation evaluated the effects of yohimbine on the ASR in healthy subjects. Seven healthy subjects received IV yohimbine (0.4 mg/kg) or saline placebo on two separate days in a randomized double blind placebo control design. A trial of 2 tone frequencies with varied intensity (90, 96, 102, 108, 114 dB) white noise, instantaneous rise time, was delivered binaurally through headphones. Tones were delivered every 25–60 sec, for a 30 ms duration. Startle testing was done 80 minutes post infusion and lasted 15–20 minutes. Sign rank testing indicated yohimbine caused an overall increase in startle amplitude, as well as significant augmentation of startle amplitude at 96, 102, 108, 114 decibels but not at the 90 dB intensity. Sign rank tests indicated a significant reduction of startle latency by yohimbine at only the 96 dB intensity. Significant correlations were observed between startle and peak anxiety, startle and plasma MHPG, peak anxiety and plasma MHPG. This study demonstrates in healthy human subjects an excitatory effect of yohimbine on the mangnitude of the ASR and a decrease in its latency. In the context of the key role of this reflex in the alarm response, this finding adds to the array of documented behavioral, biochemical and cardiovascular effects of yohimbine in humans which support the relationship between increased noradrenergic function and anxiety states.     

Pharmacological dissociation of moderate and high contextual fear as assessed by freezing behavior and fear-potentiated startle.

The amplitude of the whole-body acoustic startle response is reliably enhanced when elicited in the presence of foreground signals, such as light, previously paired with footshocks. It has been shown that this enhancement is evident by moderate fear levels, but is less affected by high fear levels. Potentiation of the acoustic startle reflex has also been reported in the presence of background cues previously associated with footshocks. However, the effects of anxiolytic drugs on different levels of fear elicited by moderate and intense contextual fear conditioning associated with startle reflex have not been examined yet. To approach this issue, we examined the effects of the anxiolytic, midazolam, on two intensities of contextual fear; freezing behavior and the startle response to loud noise. First, we compared the magnitude of the freezing behavior and the startle amplitude during the testing sessions in groups of rats submitted to fear conditioning using 0.3 and 0.6 mA as unconditioned stimuli (10 stimuli of 1 s each, intertrial interval from 60 to 180 s). Afterwards, the effects of midazolam (0.5 and 1.0 mg/kg) were assessed in these two conditions. Rats showed a potentiated startle reflex and a significant freezing behavior to moderate fear conditioning, which were both attenuated by midazolam. Higher levels of fear conditioning caused more intense freezing behavior without enhancing the startle reflex. Whereas midazolam reduced this freezing response, the startle response was unaffected. These results are indicative that anxiolytic-sensitive freezing and fear-potentiated startle are triggered by moderate contextual fear conditioning, while contextual conditioning with the use of high footshocks causes a distinct pattern of behavioral responses, which is only partially affected by midazolam. Due to the differential sensitivity to midazolam of these two patterns of startle responses generated as a function of the intensity of contextual fear conditioning, it is proposed that they represent moderate and intense aversive states that may be related to anxiety or panic/phobic conditions, respectively.     

Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam,pregabalin, and diphenhydramine

Background  Fear-potentiated startle has been suggested as a translational model for evaluating efficacy of anxiolytic compounds in humans. Several known anxiolytic compounds have been tested as well as several putative anxiolytics. Because results of these studies have been equivocal, the aim of the present study was to examine another pharmacological permutation of the human potentiated startle model by comparing two anxiolytic agents to a non-anxiolytic sedative and placebo. Methods  Twenty healthy volunteers participated in a double-blind, placebo-controlled, cross-over study with four sessions in which they received single doses of the anxiolytics alprazolam (1 mg) and pregabalin (200 mg), as well as diphenhydramine (50 mg) as a non-anxiolytic sedative control and placebo. The design included a cued shock condition that presumably evokes fear and an unpredictable shock context condition presumably evoking anxiety. Results  None of the treatments reliably reduced either fear- or anxiety-potentiated startle. Alprazolam and diphenhydramine reduced overall baseline startle. Alprazolam was found to only affect contextual anxiety in a statistical significant way after two subjects who failed to show a contextual anxiety effect in the placebo condition were excluded from the analysis. Pregabalin did not significantly affect any of the physiological measures. Discussion  The negative findings from this study are discussed in terms of methodological differences between designs and in variability of startle both between and within study participants. Conclusion  Even though fear-potentiated startle may be used to translate preclinical evidence to human populations, methodological issues still hamper the application of this model to early screening of putative anxiolytic drugs.     

Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone

The present study evaluated the role of various neurotransmitter systems in mediating buspirone's blockade of the fear-potentiated startle effect, where acoustic startle amplitude is normally increased in the presence of a light previously paired with a shock. Large lesions of the dorsal and median raphe nuclei or IP injections of the serotonin antagonists cinanserin (10 mg/kg) or cyproheptadine (5 mg/kg) did not alter fear-potentiated startle, nor did these treatments prevent buspirone (5 or 10 mg/kg SC) from blocking fear-potentiated startle. The 5-HT_1A agonist 8-OH-DPAT (2.5–10.0) did not block fear-potentiated startle even at doses that produced a marked 5-HT syndrome. Another 5-HT_1A agonist, ipsapirone (10–20 mg/kg), blocked potentiated startle only at a very high dose (40 mg/kg).p-Chlorophenylalanine andp-chloroamphetamine did not alter fear-potentiated startle. Finally, pretreatment with the benzodiazepine receptor antagonist RO-15-1788 (1 mg/kg); the opiate antagonist naloxone (2 mg/kg) or the ₂-adrenergic antagonist yohimbine (5 mg/kg) did not reduce fear-potentiated startle, nor did they prevent buspirone from blocking fear-potentiated startle. Taken together, the data do not support the hypothesis that buspirone's anxiolytic effects are mediated by actions at 5-HT_1A receptors and more generally indicate that serotonergic neurons do not play an important role in fear-potentiated startle.     

Elevated startle during withdrawal from acute morphine: a model of opiate withdrawal and anxiety

Rationale An elevated startle response has been observed in humans and animals during withdrawal from multiple substances of abuse, a phenomenon thought to reflect the anxiogenic effects of withdrawal. Although anxiety is a common symptom of opiate withdrawal, few studies have examined the effects of morphine withdrawal on acoustic startle.Objective To develop a procedure for assessing opiate dependence through measurement of the startle reflex in rats.Methods The effects of opiate withdrawal on startle were evaluated using both spontaneous and naloxone-precipitated withdrawal from an acute dose of morphine. The ability of the treatment drugs clonidine and chlordiazepoxide to block withdrawal-induced increases in startle was also tested.Results Spontaneous withdrawal from an injection of morphine sulfate produced a significant increase in acoustic startle 2 h (3.2 mg/kg) or 4 h (10 mg/kg) after drug administration. Morphine withdrawal (10 mg/kg morphine sulfate) precipitated by the opiate antagonist naloxone (2.5 mg/kg) also produced a significant increase in startle magnitude. This elevation of startle was blocked by both clonidine (35 g/kg) and chlordiazepoxide (10 mg/kg).Conclusions These data demonstrate that both spontaneous and precipitated withdrawal from an acutely administered opiate produce anxiety-like effects on acoustic startle. This paradigm may be useful in the study of anxiety and the early mechanisms of drug dependence.     

Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety

Abstract Rationale. The fear-potentiated startle paradigm [increased startle in the presence of a conditioned fear stimulus (CS)] has become increasingly popular as a tool for evaluating the potential efficacy of putative anxiolytic compounds. However, when the tested compounds also influence baseline startle, it is unclear how comparisons with control groups can best be made. Objective. To evaluate the validity of absolute difference (startle amplitude on CS minus non-CS test trials) vs. proportional increase (the absolute difference score divided by startle amplitude on non-CS test trials) scoring methods. Methods. The effect on proportional increase and absolute difference scores of baseline shifts that occur with or without concomitant increases in fear was evaluated in rats. A reliable measure should yield similar scores across shifting baselines, provided that fear levels remain constant. Results. Preexisting baseline differences, and those brought about by different startle-eliciting noise burst intensities, by strychnine injections, or by CRH infusions, each increased absolute difference scores without markedly influencing proportional change scores. These baseline differences were not associated with different fear levels. Increases in baseline startle brought about by unsignaled footshocks or by a second CS – increases which are associated with increased fear – partially occluded additional CS-induced increases using either measure. Conclusions. Across different baselines, CS-elicited fear is most accurately reflected in proportional change scores. Under certain conditions saturation effects may interfere with an accurate assessment using either measure. However, these same saturation effects may provide opportunities to explore the neural circuitry of fear and anxiety in novel ways. Electronic Publication     

Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety

Data will be reviewed using the acoustic startle reflex in rats and humans based on our attempts to operationally define fear vs anxiety. Although the symptoms of fear and anxiety are very similar, they also differ. Fear is a generally adaptive state of apprehension that begins rapidly and dissipates quickly once the threat is removed (phasic fear). Anxiety is elicited by less specific and less predictable threats, or by those that are physically or psychologically more distant. Thus, anxiety is a more long-lasting state of apprehension (sustained fear). Rodent studies suggest that phasic fear is mediated by the amygdala, which sends outputs to the hypothalamus and brainstem to produce symptoms of fear. Sustained fear is also mediated by the amygdala, which releases corticotropin-releasing factor, a stress hormone that acts on receptors in the bed nucleus of the stria terminalis (BNST), a part of the so-called ‘extended amygdala.'' The amygdala and BNST send outputs to the same hypothalamic and brainstem targets to produce phasic and sustained fear, respectively. In rats, sustained fear is more sensitive to anxiolytic drugs. In humans, symptoms of clinical anxiety are better detected in sustained rather than phasic fear paradigms.     

Increased Dopamine Receptor Activity in the Nucleus Accumbens Shell Ameliorates Anxiety during Drug Withdrawal

A number of lines of evidence suggest that negative emotional symptoms of withdrawal involve reduced activity in the mesolimbic dopamine system. This study examined the contribution of dopaminergic signaling in structures downstream of the ventral tegmental area to withdrawal from acute morphine exposure, measured as potentiation of the acoustic startle reflex. Systemic administration of the general dopamine receptor agonist apomorphine or a cocktail of the D1-like receptor agonist {"type":"entrez-protein","attrs":{"text":"SKF82958","term_id":"1156217255"}}SKF82958 and the D2-like receptor agonist quinpirole attenuated potentiated startle during morphine withdrawal. This effect was replicated by apomorphine infusion into the nucleus accumbens shell. Finally, apomorphine injection was shown to relieve startle potentiation during nicotine withdrawal and conditioned place aversion to morphine withdrawal. These results suggest that transient activation of the ventral tegmental area mesolimbic dopamine system triggers the expression of anxiety and aversion during withdrawal from multiple classes of abused drugs.